FYCOMPA (pérampanel) - Crises d’épilepsie (GTCP et EGI)
Reason for request
Favourable opinion for reimbursement in the treatment of partial-onset seizures (POS) with or without secondarily generalised seizures in patients from 4 years to 11 years of age and in the treatment of primary generalised tonic-clonic (PGTC) seizures in patients from 7 to 11 years of age with idiopathic generalised epilepsy (IGE), in combination with another anti-epileptic treatment.
What therapeutic improvement?
No clinical added value in the therapeutic strategy for the treatment of partial-onset seizures and primary generalised tonic-clonic seizures in children.
Role in the care pathway?
The objective of medicinal treatment is the absence of seizures combined with good tolerability of treatment, where possible. Where this is not possible, medicinal treatment aims to reduce the number of seizures, with the best possible quality of life. The therapeutic strategy should be tailored individually, in liaison with patients and/or their families and/or legal representatives, based on the patient’s characteristics (sex, age, etc.), seizure type, syndrome diagnosis, existing medicinal products and treatments, comorbidities and lifestyle. Epilepsy does not systematically require the prescription of a long-term treatment.
Anti-epileptic monotherapy should be used as first-line treatment. When the first-line treatment is not sufficiently effective at the maximum dose or is poorly tolerated, monotherapy using another drug (which may be a first or second-line alternative) should be initiated. The anti-epileptic drug replacement period should be carefully monitored. In the majority of cases, it is recommended to use an anti-epileptic dual therapy when two successive monotherapies, appropriate to the diagnosis of the seizures or syndrome and at optimal doses, have not enabled complete control of seizures.
Role of the medicinal product in the care pathway
FYCOMPA (perampanel) is an additional treatment option in the treatment of partial-onset seizures in patients from 4 years to 11 years of age and in the treatment of primary generalised tonic-clonic seizures in patients from 7 to 11 years of age with idiopathic generalised epilepsy.
The potential benefit of treatment with perampanel should be assessed taking into consideration the product’s tolerability and the lack of data relative to the effects of the product on other generalised seizures, such as absence and myoclonic seizures, in particular.
The Committee deems that the clinical benefit of FYCOMPA (perampanel) is substantial in the treatment of primary generalised tonic-clonic seizures, in combination with another anti-epileptic treatment, in patients from 7 years to 11 years of age with idiopathic generalised epilepsy.
Clinical Added Value
|no clinical added value||
but in view of:
the Committee considers that FYCOMPA (perampanel) provides no clinical added value (CAV V) in the therapeutic strategy for the treatment of partial-onset seizures and primary generalised tonic-clonic seizures in children.